Global Graft Versus Host Disease Treatment Market 2022-2027: Rising Number of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Graft Versus Host Disease Treatment Market (2022-2027) by Disease Type, Product, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global Graft Versus Host Disease Treatment Market is estimated to be USD 365.1 Mn in 2022 and is expected to reach USD 567.18 Mn by 2027, growing at a CAGR of 9.21%.

Market Segmentations

The Global Graft Versus Host Disease Treatment Market is segmented based on Disease Type, Product, and Geography.

• By Disease Type, the market is classified into Acute graft vs host disease, Chronic graft vs host disease, and Prophylaxis GVHD.
• By Product, the market is classified into Etanercept, Monoclonal antibodies, Thalidomide, Tyrosine kinase inhibitors, and mTOR inhibitors.
• By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Countries Studied

• America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
• Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
• Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
• Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Graft Versus Host Disease Treatment Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Graft Versus Host Disease Treatment Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Market Dynamics

Drivers

• Growing Number of Allogeneic Transplantations
• Rising Number of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants

Restraints

• High Cost of Treatment
• High Investment in the Clinical Trials

Opportunities

• Clinical Advancements in the Treatment Procedure

Challenges

• Lack of Awareness of GvHD

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics

5 Market Analysis

6 Global Graft Versus Host Disease Treatment Market, By Disease Type

7 Global Graft Versus Host Disease Treatment Market, By Product

8 Americas’ Graft Versus Host Disease Treatment Market

9 Europe’s Graft Versus Host Disease Treatment Market

10 Middle East and Africa’s Graft Versus Host Disease Treatment Market

11 APAC’s Graft Versus Host Disease Treatment Market

12 Competitive Landscape

13 Company Profiles

14 Appendix

Companies Mentioned

• AbbVie Inc.
• Accord Healthcare Ltd.
• Acrofan
• Asahi Kasei Corp.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• ElsaLys Biotech SA
• F. Hoffmann-La Roche AG
• Genzyme Corp.
• GlaxoSmithKline plc
• Incyte Corp.
• Johnson & Johnson
• Mallinckrodft PLC
• Merck & Co. Inc.
• Mesoblast Ltd.
• Neovii Biotech GmbH
• Novartis AG
• Ocugen, Inc.
• Pfizer Inc.
• Pluristem Therapeutics Inc.
• Samedan Ltd.
• Sanofi SA
• Soligenix, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ogf99k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900